CeriBell (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 15,628 shares of CeriBell stock in a transaction that occurred on Wednesday, April 23rd. The shares were sold at an average price of $15.11, for a total transaction of $236,139.08. Following the completion of the sale, the chief executive officer now owns 727,151 shares in the company, valued at $10,987,251.61. This trade represents a 2.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Xingjuan Chao also recently made the following trade(s):
- On Thursday, April 17th, Xingjuan Chao sold 5,700 shares of CeriBell stock. The shares were sold at an average price of $15.02, for a total transaction of $85,614.00.
- On Monday, April 21st, Xingjuan Chao sold 3,372 shares of CeriBell stock. The stock was sold at an average price of $15.03, for a total transaction of $50,681.16.
CeriBell Trading Up 2.7 %
CBLL stock opened at $15.49 on Friday. CeriBell has a 1-year low of $10.01 and a 1-year high of $32.75. The business's 50 day simple moving average is $19.78.
CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to analysts' expectations of $17.55 million. Equities analysts forecast that CeriBell will post -2.46 EPS for the current year.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on the company. LADENBURG THALM/SH SH initiated coverage on CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective for the company. Canaccord Genuity Group reiterated a "buy" rating and issued a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $32.50.
Get Our Latest Stock Report on CBLL
Institutional Investors Weigh In On CeriBell
Several hedge funds have recently bought and sold shares of the stock. FMR LLC acquired a new position in shares of CeriBell in the fourth quarter valued at approximately $128,120,000. TPG GP A LLC bought a new stake in CeriBell in the 4th quarter valued at $102,677,000. Red Tree Management LLC acquired a new position in CeriBell in the 4th quarter valued at $57,083,000. Yu Fan bought a new position in CeriBell during the 4th quarter worth $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd acquired a new stake in shares of CeriBell during the fourth quarter worth $28,160,000.
About CeriBell
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
